Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan

Masayuki Hashiguchi, Nobuaki Yamauchi, Takeshi Uchikura, Mayumi Mochizuki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Drug selection for the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer was analyzed pharmacoeconomically. Two patterns consisting of continuation of an NSAID plus administration of the prostaglandin (PG) preparation misoprostol (PG model) for 8 weeks and continuation of an NSAID plus administration of the proton-pump inhibitors omeprazole and lansoprazole (PPI model) for 8 weeks were examined. Decision analysis models were created on the basis of reports of clinical studies and epidemiologic studies relating to the drugs and gastric ulcer, and cost-comparative analyses were conducted based on the number of persons who had ulcer healing as health outcomes. Costs were estimated with respect to health expenditures from the third-party payer (public) perspective. In the case of continuation of an NSAID plus administration of the proton-pump inhibitor omeprazole for 8 weeks, the health outcomes improved and costs were reduced in comparison with continuation of an NSAID plus administration of misoprostol, thus making the administration of omeprazole the dominant choice. With continuation of an NSAID plus administration of lansoprazole for 8 weeks, the cost-savings of lansoprazole were inferior to those of misoprostol. The generic omeprazole product was the most cost-saving among the four drugs (misoprostol, original omeprazole product, generic omeprazole product, and lansoprazole) examined.

Original languageEnglish
Pages (from-to)585-594
Number of pages10
JournalYakugaku Zasshi
Volume128
Issue number4
DOIs
Publication statusPublished - 2008 Apr
Externally publishedYes

Fingerprint

Stomach Ulcer
Japan
Anti-Inflammatory Agents
Omeprazole
Costs and Cost Analysis
Drug Therapy
Lansoprazole
Misoprostol
Pharmaceutical Preparations
Proton Pump Inhibitors
Prostaglandins
Health Insurance Reimbursement
Decision Support Techniques
Cost Savings
Health
Health Expenditures
Patient Selection
Ulcer
Epidemiologic Studies

Keywords

  • Gastric ulcer
  • Nonsteroidal anti-inflammatory drugs
  • Pharmacoeconomics
  • Prostaglandin preparation
  • Proton-pump inhibitor

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan. / Hashiguchi, Masayuki; Yamauchi, Nobuaki; Uchikura, Takeshi; Mochizuki, Mayumi.

In: Yakugaku Zasshi, Vol. 128, No. 4, 04.2008, p. 585-594.

Research output: Contribution to journalArticle

Hashiguchi, Masayuki ; Yamauchi, Nobuaki ; Uchikura, Takeshi ; Mochizuki, Mayumi. / Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan. In: Yakugaku Zasshi. 2008 ; Vol. 128, No. 4. pp. 585-594.
@article{20985067b517448e85c1b9f9a9fa20cb,
title = "Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan",
abstract = "Drug selection for the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer was analyzed pharmacoeconomically. Two patterns consisting of continuation of an NSAID plus administration of the prostaglandin (PG) preparation misoprostol (PG model) for 8 weeks and continuation of an NSAID plus administration of the proton-pump inhibitors omeprazole and lansoprazole (PPI model) for 8 weeks were examined. Decision analysis models were created on the basis of reports of clinical studies and epidemiologic studies relating to the drugs and gastric ulcer, and cost-comparative analyses were conducted based on the number of persons who had ulcer healing as health outcomes. Costs were estimated with respect to health expenditures from the third-party payer (public) perspective. In the case of continuation of an NSAID plus administration of the proton-pump inhibitor omeprazole for 8 weeks, the health outcomes improved and costs were reduced in comparison with continuation of an NSAID plus administration of misoprostol, thus making the administration of omeprazole the dominant choice. With continuation of an NSAID plus administration of lansoprazole for 8 weeks, the cost-savings of lansoprazole were inferior to those of misoprostol. The generic omeprazole product was the most cost-saving among the four drugs (misoprostol, original omeprazole product, generic omeprazole product, and lansoprazole) examined.",
keywords = "Gastric ulcer, Nonsteroidal anti-inflammatory drugs, Pharmacoeconomics, Prostaglandin preparation, Proton-pump inhibitor",
author = "Masayuki Hashiguchi and Nobuaki Yamauchi and Takeshi Uchikura and Mayumi Mochizuki",
year = "2008",
month = "4",
doi = "10.1248/yakushi.128.585",
language = "English",
volume = "128",
pages = "585--594",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan

AU - Hashiguchi, Masayuki

AU - Yamauchi, Nobuaki

AU - Uchikura, Takeshi

AU - Mochizuki, Mayumi

PY - 2008/4

Y1 - 2008/4

N2 - Drug selection for the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer was analyzed pharmacoeconomically. Two patterns consisting of continuation of an NSAID plus administration of the prostaglandin (PG) preparation misoprostol (PG model) for 8 weeks and continuation of an NSAID plus administration of the proton-pump inhibitors omeprazole and lansoprazole (PPI model) for 8 weeks were examined. Decision analysis models were created on the basis of reports of clinical studies and epidemiologic studies relating to the drugs and gastric ulcer, and cost-comparative analyses were conducted based on the number of persons who had ulcer healing as health outcomes. Costs were estimated with respect to health expenditures from the third-party payer (public) perspective. In the case of continuation of an NSAID plus administration of the proton-pump inhibitor omeprazole for 8 weeks, the health outcomes improved and costs were reduced in comparison with continuation of an NSAID plus administration of misoprostol, thus making the administration of omeprazole the dominant choice. With continuation of an NSAID plus administration of lansoprazole for 8 weeks, the cost-savings of lansoprazole were inferior to those of misoprostol. The generic omeprazole product was the most cost-saving among the four drugs (misoprostol, original omeprazole product, generic omeprazole product, and lansoprazole) examined.

AB - Drug selection for the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer was analyzed pharmacoeconomically. Two patterns consisting of continuation of an NSAID plus administration of the prostaglandin (PG) preparation misoprostol (PG model) for 8 weeks and continuation of an NSAID plus administration of the proton-pump inhibitors omeprazole and lansoprazole (PPI model) for 8 weeks were examined. Decision analysis models were created on the basis of reports of clinical studies and epidemiologic studies relating to the drugs and gastric ulcer, and cost-comparative analyses were conducted based on the number of persons who had ulcer healing as health outcomes. Costs were estimated with respect to health expenditures from the third-party payer (public) perspective. In the case of continuation of an NSAID plus administration of the proton-pump inhibitor omeprazole for 8 weeks, the health outcomes improved and costs were reduced in comparison with continuation of an NSAID plus administration of misoprostol, thus making the administration of omeprazole the dominant choice. With continuation of an NSAID plus administration of lansoprazole for 8 weeks, the cost-savings of lansoprazole were inferior to those of misoprostol. The generic omeprazole product was the most cost-saving among the four drugs (misoprostol, original omeprazole product, generic omeprazole product, and lansoprazole) examined.

KW - Gastric ulcer

KW - Nonsteroidal anti-inflammatory drugs

KW - Pharmacoeconomics

KW - Prostaglandin preparation

KW - Proton-pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=41849115942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849115942&partnerID=8YFLogxK

U2 - 10.1248/yakushi.128.585

DO - 10.1248/yakushi.128.585

M3 - Article

C2 - 18379175

AN - SCOPUS:41849115942

VL - 128

SP - 585

EP - 594

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 4

ER -